Amgen's Phase 3 MariTide OSA trial status update: active, not recruitingSep 29Trial updateAmgenmaridebart cafraglutide
FDA approves label update for TEPEZZA; Amgen registers MariTide bioavailability studySep 23Weekly roundup, 2 itemsAmgenmaridebart cafraglutide
Amgen updates IMDELLTRA label via BLA supplement; registers romosozumab bioavailability trialSep 11Weekly roundup, 2 itemsAmgenromosozumab-aqqg
Amgen registers Phase 4 trial testing Repatha's effect on coronary plaque burdenSep 4Trial updateAmgenevolocumab
Amgen posts results for rocatinlimab AD trial, daxdilimab myositis study; mCRPC trial terminatedAug 28Weekly roundup, 3 itemsacapatamabAmgen
Tezspire meets primary endpoints in Phase III EoE trial CROSSINGAug 27Clinical readoutAmgenAstraZeneca
Amgen registers Phase 3 trial comparing subcutaneous and IV tarlatamab in relapsed ES-SCLCAug 21Trial updateAmgentarlatamab-dlle
Amgen terminates Crohn's disease collaboration with TScan TherapeuticsAug 18PartnershipAmgenTScan Therapeutics, Inc.
Amgen posts ROCKET-SHUTTLE Phase 3 rocatinlimab results; Neulasta label updated; AMG 691 trial opensAug 6Weekly roundup, 3 itemsAMG-691Amgen
Amgen updates MariTide pipeline, discontinues AMG 513, keeps pressing FDA on TAVNEOSAug 4Quarterly updateAMG-513Amgen
New Phase 2a trial registered for Amgen's xaluritamig after lutetium-177 therapyJul 30Trial updateAmgenxaluritamig
Amgen posts results for three rocatinlimab Phase 3 trials, plus CodeBreak300 and AMG 133 updatesJul 24Weekly roundup, 5 itemsAmgenmaridebart cafraglutide
Amgen posts sotorasib trial results, updates Neupogen and Repatha labels; ITP trial recruitsJul 16Weekly roundup, 5 itemsAmgenevolocumab
Amgen registers two Phase 3 extension trials for obesity drug maridebart cafraglutideJul 6Weekly roundup, 2 itemsAmgenmaridebart cafraglutide
Amgen recalls Sensipar and Corlanor lots; BKEMV biosimilar gets label updateJul 1Weekly roundup, 6 itemsAmgeneculizumab-aeeb
Sign in